Table 6. Current literature including ovarian cancer patient tissue and EGFR staining (2000-2016).
| Source [citation] | N | Country of origin | Antibody | Scoring method | Summary of results associated with EGFR expression |
|---|---|---|---|---|---|
| Alshenawy, H.A. 2010 [29] | 120 | Egypt | Monoclonal Clone 2-18C9 Pharm Dx (Dako) IHC |
Percent positivity and Intensity | Significantly poorer OS |
| Brustmann, H. 2008 [30] | 50 | Austria | Monoclonal NCL-EGFR-384 Novocastra 1:150 IHC | Percent positivity and Intensity, Membrane localization, Large tissue sections, Serous tumors only | Significantly poorer OS |
| Castellvi, J. 2006 [23] | 75 | Spain | Monoclonal DakoCytomation 1:100 IHC | Positivity Membrane localization | No significant association with OS |
| Davies, S. 2014 [18] | 202 | USA, New Mexico | Monoclonal clone 3C6, IHC | Percent positivity and Intensity Membrane localization | No significant association with PFS |
| Despierre, E. 2015 [41] | 218 | Multicenter Europe |
Cell signaling 1:50 | Percent positivity and Intensity Membrane localization | No significant association with OS |
| Demir, L 2014 [31] | 82 | Turkey | Monoclonal, clone EP38Y Abcam IHC | Percent positivity Membrane localization | No significant association with OS |
| Elie, C. 2004 [26] | 93 | France | Monoclonal clone EGFR.113 Tebu 1:10 IHC | Positivity Membrane localization FIGO III or IV | No significant association with OS |
| Engelstaedter, V. 2012 [34] | 217 | Germany | Monoclonal, clone 3C6 Ventana IHC | Positivity Membrane localization FIGO III | No significant association with OS |
| Fujiwara, S. 2012 [28] | 162 | Japan | Pharm Dx (Dako) IHC | Percent positivity and Intensity | No significant association with OS Significantly poorer PFS if co-expressed with GRP30 Significantly higher expression in tumor versus borderline malignancy (n=10) |
| de Graeff, P. 2008 [19] | 232 | Netherlands | no source IHC | Percent positivity Membrane localization | No significant association with OS Significant positivity in non-serous tumors |
| Lassus, H. 2006 [35] | 379 | Finland | Monoclonal NCL-EGFR Novocastra 1:150 IHC | Positivity Membrane localization Serous tumors only |
Significantly poorer OS and DFS |
| Lee, C.H. 2005 [24] | 103 | Canada | Monoclonal Clone 2-18C9 Dako IHC | Percent positivity FIGO III or IV | No significant association with DFS |
| Lin, C. 2009 [15] | 185 | Taiwan | Monoclonal, clone E30 Dako 1:25 IHC | Percent positivity and Intensity | Significantly higher expression in serous, endometrioid, clear cell, and mucinous tumors than normal tissue |
| Nielsen, J.S 2004 [44] | 783 | Denmark | Monoclonal, clone 113 Novocastra 1:40 IHC | Percent positivity Large tissue sections | No significant association with OS in univariate, significantly poorer OS in multivariate analysis, adjusting for age, FIGO stage, grade, subtype |
| Noske, A. 2011 [32] | 121 | Germany | Monoclonal Clone 5b7 Ventana Medical Systems IHC | Percent positivity Membrane localization | Significantly poorer OS for membrane stain and serous carcinoma |
| Psyrri, A. 2005 [16] | 150 | Greece | Monoclonal, clone H11 DAKO 1:50 IF | Percent positivity and Intensity Nuclear localization FIGO III or IV | Significantly poorer OS and DFS in univariate and multivariate analysis, adjusting for FIGO stage, grade, residual disease and chemotherapy response |
| Raspollini, M.R. 2005 [36] | 60 | Italy | Monoclonal Clone 31G7 Ventana Medical Systems | Positivity Membrane localization Large tissue sections FIGO IIIC only |
No significant association with OS |
| Skírnisdóttir, I. 2004 [21] | 212 | Sweden | Monoclonal, clone 113 Novocastra IHC | Percent positivity Membrane localization |
No significant association with OS Significantly poorer DFS for FIGO I-II Higher positivity in serous compared to clear cell carcinoma |
| Stadlmann, S. 2006 [20] | 80 | Switzerland | Monoclonal, clone 2-18C9 PharmDX (Dako) IHC | Percent positivity Membrane localization Serous tumors only | Significantly associated with EGFR amplification in both primary and recurring tumors |
| Tanaka, Y. 2011 [42] | 102 | Japan | Pharm Dx (Dako) IHC | Percent positivity FIGO II, III, IV | No significant association with OS |
| Wang, K. 2016 [37] | 242 | China | Polyclonal Santa Cruz IHC | Percent positivity and Intensity | No significant association with OS Significantly poorer OS associated with tumor stroma expression |
| Wittinger, M. 2011 [25] | 144 | Austria | Polyclonal Santa Cruz 1:100 IHC | Percent positivity and Intensity | Significantly poorer OS |
| Xia, W. 2009 [43] | 221 | USA, Texas | Nuclear stain: Polyclonal Upstate 1:150 Cytoplasmic stain: Clone EGFR.25 Novocastra IHC |
Percent positivity and Intensity | Significantly poorer OS with nuclear localization No significant association with OS in cytoplasmic stain |
| Zhang, M 2015 [27] | 161 | China | Polyclonal Santa Cruz 1:100 IHC | Percent positivity and Intensity Membrane localization |
Significantly poorer OS Significantly higher expression in serous and endometrioid tumors |
OS- overall survival, DFS – disease free survival, PFS – progression free survival, HR – hazard ratio. IHC- immunohistochemistry, IF- immunofluorescence